Virtual conference 

The Rise of Advanced Technologies in the Pharmaceutical Industry 1920x1080 (2).png

The 3-day conference will be held on November  15-17, 2021. Specialists from Deep Knowledge Group and invited business representatives will provide thoughts and findings of trends and application use cases of AI in technology, pharmaceutical, and healthcare industries.


Two DPI reports, "AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview Q4 2021" and "Landscape of Advanced Technology Companies in Pharmaceutical Industry Q4 2021" will be presented at the conference.

Biomarkers of Human Longevity Conference (1920х1080).png

Biomarkers of Human Longevity: State of the Market and Diversity of Practical Applications Q4 2021 is an upcoming 2-day virtual conference featuring talks and panel discussions among industry leaders, companies, investors and practitioners in the rapidly growing domain of Biomarkers of Human Longevity.

The Summit is a ‘who’s who’ of AI in biopharma and is your chance to engage in deep coverage of AI in drug discovery, clinical development and real-world evidence from an elite speaker line up including Sanofi, Novartis Institutes for Biomedical Research, Pfizer, Biogen, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Janssen, GSK and more who are pioneers in the movement.

The Technology Revolution of FoodTech Industry (Facebook)1200x628.webp

On "The Technology Revolution of FoodTech Industry" webinar influencers and main experts of the FoodTech industry will share their insights and researches of emerging trends and application of modern technologies in the industry. 

During this open-access event, global experts of the FoodTech industry will discuss new horizons of the market. FoodTech is the emergent sector exploring how technology can be leveraged to improve efficiency and sustainability in designing, producing, choosing, delivering and consumption of food. The FoodTech Industry is developing rapidly and includes more than 5,000 startups globally.


The Future of Space Medicine was carried out in an online format. Understanding of new technologies emerging for space medicine will become ever-more important with the soon-to-come plunging of launch prices, enabling thousands of people, many not necessarily in the best of physical health, to visit space in the near future. With that much activity, the chances of accidents will vastly increase, and many of them will need to be dealt with in space, because waiting for an ambulance to get back to Earth may be too late. But we haven’t developed protocols or procedures for surgery or burn treatments in free fall (though ironically, that may be the best environment in which to treat a burn victim, and conceivably, there could even be orbital hospitals for such cases).

GovTech Development During COVID-19 (1920x1080) 11 (2).webp

GovTech Development During COVID-19: How Technologies Have Helped’ is an upcoming conference dedicated to coverage of the most effective E-government and GovTech solutions, implemented during the COVID-19 period. 

The event will bring together policy-makers, government officials and field experts all over the world to share their experiences and insights learnt from the pandemic. Also, the expansion of E-government and GovTech tools usage will be considered for the Post-pandemic world. Lastly, the further course of global fight against coronavirus and the necessary steps we have taken to consideration at this point will be discussed.

Femtech Conference 1920x1080.webp

FemTech Advancing Women's Wellness and Lifespan was a virtual 1-day conference which had two panels, 13 speakers, over 220 registrants and 100+ attendees who are FemTech founders & CEOs, investors, physicians, scientists, influencers and other key players.

The event was focused on the impact of technologies on women’s health and lifespan and how FemTech contributes to women’s Longevity in general. During the event, panelists shared their insights about new possibilities in the rapidly developing FemTech market, covering its cornerstone sub sectors such as Women’s Longevity, Reproductive Health, AI for Women’s Health, Mental Health & Healthy Lifestyle, General Healthcare, and Advanced P4 Medicine for Women.

Staying Healthy in Space (1920x1080) (1).png

Staying Healthy in Space was a virtual conference that took place on September 29, 2021 (5:00 pm - 9:00 pm, BST) in which speakers from the space-medical community discussed the opportunities and challenges presented by the coming rapid growth in the number of humans working, playing, and perhaps even living in space – as a key part of expanding human presence in space and in generating economic benefit both off-planet and terrestrial, from space activities. Speakers addressed the issues, potential solutions to them, and identify areas of necessary research to better understand both the issues and best solutions.

Femtech Conference 1920x1080 (1)-min.webp

The virtual conference "FemTech Industry Landscape 2021: Discovering New Horizons" held on July 29, 2021, where professionals from FemTech Analytics and invited guest speakers who are Founders & CEO of FemTech companies and start-ups, Healthcare Innovators, Investors and Hubs, Women Influencers and Enthusiasts shared insights, findings and personal experience about new possibilities and cutting-edge technologies in fast developing FemTech market.

All Speakers Banner V2.png

Longevity.International presents: Biomarkers Of Human Longevity” was a virtual 1-day conference that took place June 30, 2021 featuring presentations from a variety of companies, key players and thought-leaders active within the Biomarkers of Human Aging and Longevity Industry.

The event explored the present state of the industry, as well as key strategic challenges and opportunities for translating the potentials of Biomarkers of Human Longevity from theory into practice.

Screenshot 2021-06-07 at 22.41.47.png

"Practical Applications of Mitochondria Research for Human Longevity and Space Medicine" was a virtual conference that took place June 9-10, 2021, where professionals from Aging Analytics Agency and guest speakers who are Practical Longevity Experts, Space Medicine Experts and Women Influencers shared insights, findings and personal experiences about the Role of Mitochondria in The Practical Human Longevity and Scientific Approaches to Women For Extending Reproductive Longevity.

Add a subheading (1).png

The newest computational approach to drug repositioning showing the greatest promise is AI and machine learning. With a drug-repurposing strategy, AI can quickly detect drugs that can fight against emerging diseases (such as Covid-19) as well as existing diseases.

The AI Driven Drug Repositioning & Repurposing Summit will bring together 80+ leaders in repurposing and pioneers in AI and machine learning to strategize how repurposing can reach its full potential to: 

  • Improve time and cost savings of drug development

  • Leverage the safety advantage in reducing development risk

  • Unlock market potential advantage

  • Improve return on investment for repurposed drug

AI-driven webinar (2).jpeg

Webinar held on April 13, 2021. Analysts from Deep Pharma Intelligence and guest speakers shared insights and findings about trends and application use cases of artificial intelligence (AI) in the pharmaceutical research, biotech, and healthcare tech, focused specifically on tackling the coronavirus pandemics. The event featured a summary of key players, technologies and trends, including R&D and business aspects, as well as investment trends on the cross-roads of AI and COVID-19 therapeutics and tools.

0 (common) (1).png

Webinar held on March 3, 2021. It presented key findings and insights from Deep Pharma Intelligence AI in the Pharma Investment Digest.

The event provided a summary of key players, trends in the private equity and venture capital ecosystem, with a focus on the growing maturity of the AI market in Pharma, and key takeaways for investors in 2021.

DPI AI in Pharma Webinar.png

Day 1 (Top AI in Pharma Deals, Trends & Partnerships 2020-Q1 2021) featured presentations and a roundtable discussion on the biggest deals, partnerships, collaborations, and industry events in the AI in Pharma sector from 2020 - 2021.


Day 2 (Investment and M&A Deals: AI in Pharma Market 2021) featured talks and a panel discussion on key players, trends in the private equity and venture capital ecosystem, focusing on the increasing market maturation of AI in Pharma, and key take-aways for investors in 2021.

0 (common) (2).png

Webinar held on March 2, 2021. It presented key findings and take-aways from Deep Pharma Intelligence's newest special analytical case study.

Webinar held on March 2, 2021. It presented key findings and take-aways from Deep Pharma Intelligence's newest special analytical case study.

Add a subheading (2).png

The AI-ML: Drug Discovery Summit is the industry’s definitive guide to translating the wealth of tech available to successfully implement a working and practically effective drug discovery and development platform.

Designed with leading AI experts from R&D and clinical departments across big pharma, biotech, and academia, this year’s forum features 3 days of real-world case studies and interactive discussions. As such, the 2021 AI-ML Summit will provide you with a roadmap to augmented R&D and clinical decision making with reduced failure rates, increased speed, and improved margins.


Deep Pharma Intelligence team introduced the company and its founding partners Deep Knowledge Analytics and BiopharmaTrend, and shared their insights and statistics about the Pharmaceutical Artificial Intelligence (AI) sector, including current trends, leaders in the “AI Race”, key R&D partnership and major investment deals, and latest industry developments. The company has paid particular attention to investment opportunities in this increasingly attractive market.

Add a subheading (4).png

The 3rd Annual AI-ML: Drug Discovery & Development Summit is the industry’s definitive guide to translating the wealth of tech available to successful, efficacious and efficient R&D processes. With 3 days of real-world case studies, this summit will provide the roadmap to augmented R&D decision making with reduced failure rates, increased speed and improved margins.

This year’s summit will take a deeper look at:

  • Target, pathway and molecule selection – identifying which will treat individual disease indications better

  • Predictive preclinical models – knowing from the beginning how drug candidates will react when administered to in vivo and in vitro models

Add a subheading (3).png

Building on the success in 2019, the 2nd Longevity Therapeutics 2020 Summit will once again return to San Francisco. As the only industry-led and end-to-end longevity meeting, we will hear success stories in the last 12 months and explore what’s next to help you accelerate your pipeline into clinic! Uniting biotech drug developers, academics, investors and pharma companies endeavoring to develop innovative anti-aging drugs and overcome key preclinical, translational, clinical and regulatory challenges going forward.

Add a subheading (5).png

Welcome to the AI Applications in Biopharma Summit; a new kind of collaborative experience where the industry’s top science minds, AI technology experts and strategy leaders share detailed use cases to help each other build out the adoption of AI technology to improve patients’ lives.

The Summit is a ‘who’s who’ of AI in biopharma and is your chance to engage in deep coverage of AI in drug discovery, clinical development and real-world evidence from an elite speaker line up including Sanofi, Novartis Institutes for Biomedical Research, Pfizer, Biogen, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Janssen, GSK and more who are pioneers in the movement.


The world’s first international, cross-border, cross-sector summit on International Longevity Policy and Governance as part of Longevity Forum’s Longevity Week 2019, bringing together world-leading policy experts, representatives of government bodies, departments, healthcare and finance ministries, executives of healthcare and financial corporations to discuss, network and collaborate on initiatives to promote international longevity development.

This half-day conference looked at the international response to harnessing the opportunities of an ageing demographic, and what lessons can be learned and shared across countries from a policy perspective.


Episode 1 of the new series Practical Human Longevity focused on market-ready technologies and approaches for Intermittent Hypoxia, Hyperoxia and their relation to Mitochondrial Aging and Healthy Human Longevity. Kaminskiy and Prokopov considered the pros and cons of different approaches within this general paradigm during their discussion. They showcased the tangible results on health and performance that Kaminskiy has experienced since beginning to integrate these technologies into his daily Personal Longevity Regime, followed by a keynote lecture on the tangible links between intermittent hypoxia and hyperoxia and human aging and Longevity.


The inaugural, exclusive and invitation-only AI for Longevity Summit, organized at King’s College London, brought together leading scientists, industry players, and experts to highlight the latest advances in Artificial Intelligence for Longevity and the practical implementation of longevity technologies and therapeutics. It was the first in a series of conferences, which we expect to become the world-leading forum on AI for Longevity. 

AI for Longevity Summit was organised by Aging Research at King’s (ARK) and AI Longevity Consortium at King’s College London, and was supported by Biogerontology Research Foundation, Aging Analytics Agency and Deep Knowledge Ventures.

targ conf.webp

Targeting Metabesity 2019 conference focused on the prevention of noncommunicable diseases and the treatment of age-related health dysfunctions to extend health-adjusted life expectancy. The conference, was held October 15-16, 2019 at the Carnegie Institution for Science in Washington, D.C., addressed one of the important issues in healthcare: the constellation of major chronic diseases, including diabetes, cardiovascular disease, dementia, cancer, and the aging process, that are considered to be the “slow motion disaster”.

King's College Longevity Summits: AI, Policy, Finance



AAA Logo all colored.png

Landmark Summits Reveal the Rise of Longevity Technocracies and MegaHubs at the Frontier of Longevity Policy and Governance


Launch of UK’s First AI for Longevity Hub at King’s College London and its Bold Plans for 2020 and Beyond

Small_DKV_logo Brain copy.jpg

Landmark Summits Reveal How the Future of National Economies Will Be Reshaped by the Intersection of AI, Longevity, Finance and Governance


How to add five extra healthy years to our lives through a new social contract - the focus at International Longevity Policy and Governance Summit launch


“Ageing is viewed with trepidation by some but you can take a lot of the uncertainty out of it by planning for the long-term. Taking better care of our health, maintaining diverse relationships, saving for retirement and being open to learning and new work opportunities can make longevity a very positive experience. Our intent with the Ready for 100 report is to get people to re-imagine what an amazing experience life to 100 could be and to inspire the changes that will make this a reality for future generations. As medical costs continue to rise, we must evaluate the role we can play in making healthcare more affordable and accessible. As insurers, this means changing the way we engage with customers. We want to go beyond covering their medical bills to coming up with innovative solutions that will make our customer healthier and wealthier”


- Wilf Blackburn, CEO of Prudential Singapore


"I believe that we are at a pivotal moment in healthcare IT where AI could fundamentally support the improvement in patient care and so outcomes. The key here is to introduce AI in to the clinical pathway where it is seen as a positive disruption, not negative or of no value. There is a fundamental challenge and that will be the ability to explain and be transparent in the development and deployment (interoperability) of the AI solution. This includes being able to explain to patients, families, carers and of course health professionals. The economic value will need to be considered in the eventual outcome of this enormously interesting time in healthcare transformation."


- Craig Rhodes, EMEA Industry Lead for Artificial Intelligence Healthcare and Life Science at NVIDIA


"The application of AI for Longevity will bring the greatest real-world benefits to the industrialization of Longevity to scale, and will serve as the main driver of progress in the widespread extension of Healthy Longevity for all segments of society.”

“AI for Longevity is an underrepresented sector in the Longevity Industry despite having more potential to increase healthy Longevity in the short term than any other sector. It is our aim to change that with the launch of the Longevity AI Consortium at King’s College London, which will work to facilitate the shift from treatment to prevention and from preventive medicine to real-world precision health.”


- Dmitry Kaminskiy, General Partner of Deep Knowledge Group and Longevity.Capital


"The United Kingdom is in a unique position, having prioritised both its longevity and AI industries in two of its four Industrial Strategy Grand Challenges. Given its strengths in AI and longevity, and its expertise as a global leader in fintech and life sciences, it can develop the healthy longevity marketplace to scale internationally.”


- Eric Kihlstrom, Partner at Longevity.Capital and Director of Industry Collaboration, Longevity International UK


“AI holds enormous potential to rapidly accelerate the implementation of Longevity R&D. The nation is home to multiple centres of AI for Healthcare, but not a single Longevity AI Consortium. We are changing this through our unique academic-industry focus on preventive and personalised physical, mental and financial health, marking us out from other AI and Ageing centres around the world”


- Richard Siow, Ph.D., Director, Longevity AI Consortium, King’s College London


“Unless drastic action is taken, people will suffer lower quality wellbeing during a longer lifespan. This could become the next global crisis after climate change. The Longevity AI Consortium is unique in its focus on preventive health, addressing the social determinants of health at the root of inequalities.”


- Tina Woods, CEO, Longevity International UK